Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.52 |
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | IL2 | P60568 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540135 | 1.00 | MDM2 (0.52) | MDM2MDM4TP53PTPN1ALB | |
| SCHEMBL15083325 | 1.00 | MDM2 (0.52) | MDM2MDM4TP53PTPN1ALB | |
| SCHEMBL16287905 | 1.00 | MDM2 (0.52) | MDM2MDM4TP53PTPN1ALB | |
| SCHEMBL120627 | 0.92 | MDM2 (0.54) | MDM2MDM4TP53PTPN1SLC17A5 | |
| SCHEMBL29400931 | 0.92 | MDM2 (0.54) | MDM2MDM4TP53PTPN1SLC17A5 | |
| SCHEMBL29445603 | 0.92 | MDM2 (0.54) | MDM2MDM4TP53PTPN1SLC17A5 | |
| SCHEMBL3728822 | 0.92 | MDM2 (0.54) | MDM2MDM4TP53PTPN1SLC17A5 | |
| SCHEMBL29908133 | 0.92 | MDM2 (0.54) | MDM2MDM4TP53PTPN1SLC17A5 | |
| SCHEMBL119539 | 0.92 | MDM2 (0.54) | MDM2MDM4TP53PTPN1SLC17A5 | |
| SCHEMBL30861897 | 0.91 | PTPN1 (0.51) | MDM2MDM4TP53PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| EP-4580686-A1 | HALOGENATED SOMATOSTATIN ANALOGS WITH MULTIPLE SOMATOSTATIN RECEPTOR SUBTYPE SELECTIVITY | Grafton Therapeutics Sàrl (CH) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024047112-A1 | HALOGENATED SOMATOSTATIN ANALOGS WITH MULTIPLE SOMATOSTATIN RECEPTOR SUBTYPE SELECTIVITY | SOMTHERANOSTICS SARL (CH) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | MDM2 2401/4885MDM4 3559/4885TP53 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.